Opinion|Videos|October 7, 2024
ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
- Comparing the two clinical trials, what were some significant differences between them?
Advertisement
Related to this article
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Advertisement
Advertisement
Trending on Contagion Live
1
Ceftriaxone Safety: Separating Signal From Risk
2
A Pennsylvania Teen Dies From Rare Measles Neurological Complication
3
Revisiting Whether Cefepime Raises Mortality Risk
4
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
5